1. Patients in the no test scenario all enter the model at A, while patients in the test scenario enter the model at either A or B dependent upon test result. Patient flow between each 3-month model is represented at the leaf nodes. Where patients reach the Markov model (model D) before the end of 12 months, the first cycles (up until 12 months) are treated as the run-in period. DRESS: drug reaction with eosinophilia and symptomatic symptoms; SJS: Stevens-Johnson syndrome; sUA: serum uric acid concentration; TEN: toxic epidermal necrolysis.
From: Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Rheumatology (Oxford). 2017;56(10): doi: /rheumatology/kex253
Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

2. (L,H) and (H,L) indicate whether the range tested is displayed as low–high or high–low, respectively. The vertical line at £ per QALY gained represents the ICER corresponding to the base case analysis. ICER: incremental cost effectiveness ratio; QALY: quality-adjusted life-year; sUA: serum uric acid level.
From: Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Rheumatology (Oxford). 2017;56(10): doi: /rheumatology/kex253
Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please

3. QALY: quality-adjusted life-year.
From: Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Rheumatology (Oxford). 2017;56(10): doi: /rheumatology/kex253
Rheumatology (Oxford) | © The Author Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please